Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Reilly

Showing results (341-350 of 382) with videos related to

Pageof 39
Sort By:
Journal of Neurology, Neurosurgery, and Psychiatry|June 26, 2014
An evaluation of the role of environmental factors in the disease penetrance of cervical dystoniaAnna Molloy, Okka Kimmich, Laura Williams, et al.
Investigational New Drugs|April 21, 2015
A phase 1 study of ABT-806 in subjects with advanced solid tumorsJames M Cleary, David A Reardon, Nilofer Azad, et al.
Journal of Neuro-Oncology|January 31, 2021
Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFRKedar S Vaidya, Michael J Mitten, Adelyn L Zelaya-Lazo, et al.
Frontiers in Neurology|June 21, 2021
Dystonia Management: What to Expect From the Future? The Perspectives of Patients and Clinicians Within DystoniaNet EuropeMarenka Smit, Alberto Albanese, Monika Benson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2018
First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid TumorsJohn H Strickler, Colin D Weekes, John Nemunaitis, et al.
Plos One|June 7, 2014
A method to assess adherence in inhaler use through analysis of acoustic recordings of inhaler eventsShona D'Arcy, Elaine MacHale, Jansen Seheult, et al.
Molecular Cancer Therapeutics|February 6, 2016
ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR EpitopeAndrew C Phillips, Erwin R Boghaert, Kedar S Vaidya, et al.
Cureus|May 28, 2026
Systems-Based Practice Core Competency: A Survey of Physicians' PerspectivesAmi L DeWaters, Britta L Thompson, Lindsay Mazotti, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 29, 2021
A Phase 1 and Biodistribution Study of ABT-806i, an <sup>111</sup>In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806Hui K Gan, Matthew Burge, Benjamin Solomon, et al.
Molecular Cancer Therapeutics|August 28, 2020
Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody-Drug ConjugateMark G Anderson, Hugh D Falls, Michael J Mitten, et al.
Pageof 39

Showing results (341-350 of 382) with videos related to

Sort By:
Pageof 39
Journal of Neurology, Neurosurgery, and Psychiatry|June 26, 2014
An evaluation of the role of environmental factors in the disease penetrance of cervical dystoniaAnna Molloy, Okka Kimmich, Laura Williams, et al.
Investigational New Drugs|April 21, 2015
A phase 1 study of ABT-806 in subjects with advanced solid tumorsJames M Cleary, David A Reardon, Nilofer Azad, et al.
Journal of Neuro-Oncology|January 31, 2021
Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFRKedar S Vaidya, Michael J Mitten, Adelyn L Zelaya-Lazo, et al.
Frontiers in Neurology|June 21, 2021
Dystonia Management: What to Expect From the Future? The Perspectives of Patients and Clinicians Within DystoniaNet EuropeMarenka Smit, Alberto Albanese, Monika Benson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2018
First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid TumorsJohn H Strickler, Colin D Weekes, John Nemunaitis, et al.
Plos One|June 7, 2014
A method to assess adherence in inhaler use through analysis of acoustic recordings of inhaler eventsShona D'Arcy, Elaine MacHale, Jansen Seheult, et al.
Molecular Cancer Therapeutics|February 6, 2016
ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR EpitopeAndrew C Phillips, Erwin R Boghaert, Kedar S Vaidya, et al.
Cureus|May 28, 2026
Systems-Based Practice Core Competency: A Survey of Physicians' PerspectivesAmi L DeWaters, Britta L Thompson, Lindsay Mazotti, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 29, 2021
A Phase 1 and Biodistribution Study of ABT-806i, an <sup>111</sup>In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806Hui K Gan, Matthew Burge, Benjamin Solomon, et al.
Molecular Cancer Therapeutics|August 28, 2020
Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody-Drug ConjugateMark G Anderson, Hugh D Falls, Michael J Mitten, et al.
Pageof 39